NCT00617188View on ClinicalTrials.gov

Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

July 31, 2008

Conditions
Ovarian Cancer
Interventions
DRUG

Fulvestrant

Fulvestrant, 500 milligrams (mg) intramuscularly (IM) on Day 1, 250 mg IM on Day 15, and 250 mg IM on Day 29 and every 28 days thereafter until either intolerance or disease progression.

Trial Locations (1)

55455

Masonic Cancer Center at University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT00617188 - Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer | Biotech Hunter | Biotech Hunter